Akebia Ther Stock Investor Sentiment

AKBA Stock  USD 1.98  0.06  2.94%   
About 66% of Akebia Ther's investor base is looking to short. The analysis of the overall investor sentiment regarding Akebia Ther suggests that many traders are alarmed. The current market sentiment, together with Akebia Ther's historical and current headlines, can help investors time the market. In addition, many technical investors use Akebia Ther stock news signals to limit their universe of possible portfolio assets.
  

Akebia Ther Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Akebia Ther can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at news.google.com         
Is Akebia Therapeutics Stock Outpacing Its Medical Peers This Year - Yahoo Movies UK
Google News at Macroaxis
over six months ago at news.google.com         
Akebia Therapeutics Surpasses Q2 Earnings and Revenue Estimates - Yahoo Movies UK
Google News at Macroaxis
over six months ago at news.google.com         
Akebia Therapeutics Upgraded by StockNews.com to Buy - Defense World
Google News at Macroaxis
over six months ago at investing.com         
H.C. Wainwright lifts Akebia shares target following FDA approval
Investing News at Macroaxis
over six months ago at bizjournals.com         
Two years after initial rejection, Akebias anemia drug finally gets FDA approval
bizjournals News
over six months ago at finance.yahoo.com         
UPDATE 1-U.S. FDA approves Akebias anemia drug
Yahoo News
over six months ago at finance.yahoo.com         
FDA Approves For Akebia Therapeutics Vafseo For Kidney Disease Associated Anemia
Yahoo News
over six months ago at benzinga.com         
FDA Approves For Akebia Therapeutics Vafseo For Kidney Disease Associated Anemia
benzinga news
over six months ago at zerohedge.com         
Stocks Set To Close Blowout Week, Month And Quarter At All-Time High Gold Soars To Record
news
over six months ago at statnews.com         
How GLP-1s moved from research labs to national TV
news
over six months ago at seekingalpha.com         
Biggest stock movers today RH, AKBA, and more
seekingalpha News
over six months ago at finance.yahoo.com         
FDA approves Akebia anemia pill, two years after rejection
Yahoo News
over six months ago at finance.yahoo.com         
Akebia Receives FDA Approval of Vafseo Tablets for the Treatment of Anemia due to Chronic Kidney Dis...
Yahoo News
over six months ago at finance.yahoo.com         
U.S. FDA approves Akebias anemia drug
Yahoo News
over six months ago at news.google.com         
Is Akebia Therapeutics Inc Stock at the Top of the Biotechnology Industry - InvestorsObserver
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Akebia Ther that are available to investors today. That information is available publicly through Akebia media outlets and privately through word of mouth or via Akebia internal channels. However, regardless of the origin, that massive amount of Akebia data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Akebia Ther news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Akebia Ther relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Akebia Ther's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Akebia Ther alpha.

Akebia Ther Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024
10/15/2024
2
Akebia Therapeutics Given Buy Rating at HC Wainwright
10/23/2024
3
Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights
11/01/2024
4
Acquisition by Rogers Michael W of 30000 shares of Akebia Ther subject to Rule 16b-3
11/05/2024
5
Akebia Ther earnings missed by 0.04, revenue fell short of estimates
11/07/2024
6
Earnings call Akebia reports Q3 results, gears up for Vafseo launch
11/08/2024
7
Akebia Therapeutics Downgraded to Sell Rating by StockNews.com
11/22/2024
8
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
12/03/2024
9
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 - The Eastern Progress Online
12/06/2024

Complementary Tools for Akebia Stock analysis

When running Akebia Ther's price analysis, check to measure Akebia Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akebia Ther is operating at the current time. Most of Akebia Ther's value examination focuses on studying past and present price action to predict the probability of Akebia Ther's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akebia Ther's price. Additionally, you may evaluate how the addition of Akebia Ther to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine